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Abstract
Protein microarrays have been recently
employed for signal pathway profiling and high-
throughput protein expression analysis. Reverse-
phase arrays, where the array consists of
immobilized analytes and lysates has especially
shown promise in low abundance analyte detec-
tion and signal pathway profiling using phos-
pho-specific antibodies. A limitation to current
reverse phase array methodology is the inabil-
ity to multiplex proteomic-based endpoints as
each array can only report one analyte end-
point. In this study, we report on the use of a
dual dye based approach that can effectively
double the number of endpoints observed per
array allowing, for example, both phosphospe-
cific and total protein levels to be measured and
analyzed at once. The method utilizes antibody
bound dyes that emit in the infrared spectral
region as a means of sensitive and specific
detection.
Key Words: Proteomics; signal profiling; networks;
protein microarrays.
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Introduction
An important goal of proteomics is to char-
acterize and develop “circuit maps” of cellu-
lar signaling pathways in normal and diseased
cells. Defective, hyperactive, or dominating
signal pathways may drive cancer growth,
survival, invasion, and metastasis (1–7). Map-
ping the information flow through signaling
pathways in normal and cancer cells may
serve as a means to identify key alterations
that occur during tumor progression and pro-
vide targets for rational, molecular-targeted
drug design. With the advent of molecular tar-
geted therapeutics, the identification, charac-
terization, and monitoring of the signaling
events within actual human biopsies will be
critical for patient-tailored therapy.
In the past, efforts to elucidate the activa-
tion of signaling pathway events have relied
mainly on either gene microarray/gene-based
analysis and bioinformatic tools to help infer
coordinate upstream signaling events or two
dimensional-polyacryalmide gel electrophore-
sis (2D-PAGE) coupled with phosphorylation
detection by immunoblotting (8–16). Unfortu-
nately, coordinate gene transcription profiling
cannot accurately reflect the posttranslational
modifications such as protein phosphorylation
that are the drivers of the cellular signaling
processes. Immunoblotting techniques often
require considerably greater amounts of test
material than can be provided by clinical sam-
ples. To understand the state of cellular sig-
naling, new technologies that can characterize
and directly monitor the activity and protein
phosphorylation of various signaling path-
ways in small quantities of tumor tissue
would be beneficial for both the identification
of important targets for therapeutics and
assessing the efficacy of these therapies.
Reverse-phase protein microarrays represent a
technology uniquely suited to screening a
broad range of pathway targets in large num-
bers of tumors simultaneously in a high-
throughput manner (17–23). Reverse-phase
arrays are amenable for analysis of biopsy
material and involve spotting nanoliter quanti-
ties of cellular lysates onto immobilized sup-
ports to allow for probing with specific
antibodies. In past studies, analyte detection
was performed by colorimetric based detection
using tyramide amplification (17–23). While
this method remains extremely sensitive and
reproducible, the end user is unable to analyze
more than one analyte per array. For example,
analysis of phosphorylation of extracellular
signal-regulated kinase (ERK) would require
two array slides, one for the phospho-specific
antibody readout and one for the total ERK
report. A method that could determine the
levels of both from the same material spotted
on the same slide could, in effect, double the
number of endpoints one could analyze
for a given amount of lysate. In this study,
we employed a two-dye fluorescent detection
system (Fig. 1) using secondary antibodies that
have been labeled with fluorochromes that can
be detected simultaneously at both 700 nm and
800 nm wavelengths. The choice of near
infrared (IR)-based dyes for this study was
based on their reported performance in West-
ern blot applications in which highly sensitive
detection was observed on a nitrocellulose sub-
stratum, the same material used for the reverse
phase protein microarray studies. These IR flu-
orochromes are uniquely suited for use on
nitrocellulose materials because background
autofluorescence from the nitrocellulose and
cellular material at infrared (IR) wavelengths




Frozen breast tumor tissues were collected
at the Lombardi Cancer Institute, Georgetown
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University, Washington DC. The tissues were
anonymized and approved for use by the
National Cancer Institute Office of Human
Subjects Research. The histopathology of each
case was confirmed by a pathologist prior to
being used in these studies.
Tissue Processing and Microdissection
Eight millimeter frozen tissue sections were
placed on uncoated glass slides and stored at
–80°C prior to use. Immediately before dissec-
tion, the sections were thawed and fixed in
70% ethanol for 5 s, stained with hematoxylin
for 8 s and dehydrated in 70, 95, and 100%
ethanol for 1.5 min each, followed by xylene
for 2 min, and then air-dried. The 70% ethanol
and hematoxylin staining solutions were sup-
plemented with Complete™ Mini protease
inhibitor tablets (Roche Applied Science, Indi-
anapolis, IN). Tumor epithelial cells or other
relevant cell populations were microdissected
with a Pixcell II Laser Capture Microdissection
system (Arcturus, Mountain View, CA).
Approximately 5000 LCM shots (20,000–25,000
cells) were microdissected for each case
and stored on microdissection caps at –80°C
until lysed.
Cell Lysis and Cellular Lysate Arraying
Microdissected cells were lysed directly
from the microdissection caps into 50 µL of
lysis buffer containing a 11 mixture of 2X Tris-
Glycine SDS Sample buffer (Invitrogen Life
Technologies, Carlsbad, CA) and Tissue Pro-
tein Extraction Reagent (Pierce, Rockford, IL)
plus 2.5% β-mercaptoethanol for 30 min at
75°C. The samples were boiled for 8 min, cen-
trifuged briefly and stored at 4°C. Immediately
prior to arraying, lysates were loaded into a
384-well plate and serially diluted with lysis
buffer into a 10-point curve ranging from undi-
luted to 1:256. Approximately 60 nL of each
sample was spotted onto nitrocellulose-coated
glass slides (Schleicher and Schuell Bioscience,
Keene, NH) with a GMSE 470 microarrayer
(Affymetrix, Santa Clara, CA). Spot sizes were
approx 500 µm. Slides were stored desiccated
at –20°C. For estimation of total protein
amounts, selected arrays were stained with
Sypro Ruby Protein Blot Stain (Molecular
Probes, Eugene, OR) according to the manu-
facturer’s instructions and visualized on a Flu-
orchem™ imaging system (Alpha Innotech,
San Leandro, CA). One day prior to antibody
staining, the lysate arrays were treated with
Reblot™ antibody stripping solution (Chemi-
con, Temecula, CA) for 15 min at room tem-
perature, washed 2 × 5 min in PBS, and then
incubated overnight in blocking solution (1 g
I-block [Tropix, Bedford, MA], 0.1% Tween-20
in 500 mL PBS) at 4°C with constant rocking. 
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Fig. 1. Protocol for near infrared reverse phase array
detection. Lysates from cell lines or patient samples
procured via laser capture microdissection are
arrayed in a miniature dilution curve on nitrocellu-
lose coated glass slides. The slides are blocked, pri-
mary antibody is added and the slide is incubated for
at least 30 min.The slide is then washed several times
with PBS, and the IR dye-labeled secondary antibod-
ies are added, and allowed to incubate at least 30
min. The slides are washed several times with PBS,
and scanned with an image analyzer capable of
detecting IR-based dyes in two channels (e.g., LI-COR
Odyssey).
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
Reverse Phase Array Colorimetric 
Detection
Blocked arrays were stained with antibod-
ies on an automated slide stainer (Dako
Cytomation, Carpinteria, CA) using the Cat-
alyzed Signal Amplification System kit accord-
ing to the manufacturer’s recommendation
(CSA; Dako Cytomation). Briefly, endogenous
biotin was blocked for 10 min using the biotin
blocking kit (Dako Cytomation), followed by
application of protein block for 5 min; primary
antibodies were diluted in antibody diluent
and incubated on slides for 30 min and
biotinylated secondary antibodies were incu-
bated for 15 min. Signal amplification involved
incubation with a streptavidin-biotin-peroxi-
dase complex provided in the CSA kit for
15 min, and amplification reagent, (biotinyl-
tyramide/hydrogen peroxide, streptavidin-
peroxidase) for 15 min each. Development was
completed using diaminobenzadine/hydro-
gen peroxide as the chromogen/substrate.
Slides were allowed to air dry following
development.
Primary and secondary antibodies and dilu-
tions used in these studies were: rabbit anti-
extracellular signal-regulated kinase (ERK)1/2
1200 (Cell Signaling Technology); rabbit
anti-phosphoERK1/2 T202/Y204 11000 (Cell
Signaling Technology); biotinlyated goat anti-
rabbit IgG (H+L) 1:5000 (Vector Laboratories,
Burlingame, CA); and biotinylated rabbit anti-
mouse IgG 1:10 (Dako Cytomation).
Reverse Phase Array Infrared Detection 
Primary and secondary antibodies were
obtained from commercial sources and were
used at the working dilutions listed below.
Rabbit anti-ERK 1/2 IgG (Cell Signaling Tech-
nology) and mouse anti-phospho ERK 1/2
IgG (Santa Cruz, Inc.) were used at a 1:100
dilution and 1:333 dilution respectively. Rabbit
anti-phospho-PKC-α IgG and mouse anti-
PKC-α (Upstate Biotech, Lake Placid, NY)
were both used at a 1:250 dilution. All primary
antibodies were diluted in I-Block supple-
mented with 0.1% Tween-20. IRDye™ 800CW-
labeled goat anti-rabbit IgG and goat
anti-mouse IgG (Rockland Immunolochemi-
cals, Gilbertsville, PA) were used at a 1:5000
dilution. Alexa Fluor® 680 goat anti-mouse
IgG and anti-rabbit IgG (Molecular Probes,
Eugene OR) were used at a 1:5000 dilution).
Secondary antibodies were diluted in I-Block
supplemented with 0.02% sodium dodecyl
sulfate (SDS) and 0.2% Tween-20. The slides
were incubated with primary antibodies for
30–120 min, washed twice for 5 min each with
TBS-T wash buffer (DAKO Cytomation) and
then incubated with infrared dye labeled sec-
ondary antibodies for 30 min. The arrays were
washed twice for 5 min each with TBS-T wash
buffer, air dried and scanned on an Odyssey™
Infrared Imager (LI-COR Biosciences, Lincoln,
NE) at 42 µm resolution. The images were
analyzed using Odyssey software. Back-
ground was subtracted from the intensity
values before the values were plotted as a
graph. 
To assess the potential for antibody inter-
ference when two antibodies are employed
simultaneously on the same array and spot,
A431 cells were treated with 100ng/mL EGF
(Upstate Biotech) for 7.5 min, and then lysed
in Laemmli’s buffer. NIH3T3 cells were treated
with 50ng/mL PDGF for 7.5 min, and then
lysed in Laemmli’s buffer. Approximately 0.5
to 1 µg of protein was loaded per well onto a
polyacrylamide gel. Following electrophoresis,
the proteins were transferred to a nitrocellu-
lose membrane (Osmonics MSI NitroBind™,
Fisher Scientific, Pittsburgh, PA). Membranes
were blocked in Odyssey blocker for 1 h. Pri-
mary antibodies were diluted in Odyssey
blocker supplemented with 0.1% Tween-20.
The blocked membranes were incubated with
primary antibodies specific for either the pan-
protein, the phosphorylated protein, or both
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for 1 h followed by three washes for 5 min
each in PBS-T (PBS plus 0.5% Tween-20). Anti-
mouse and anti-rabbit secondary antibodies
diluted in Odyssey blocker and labeled with
either Alexa Fluor680 or IRDye800CW were
added and the membranes were incubated for
30 min. Following three washes for 5 min each
with PBS-T, the membranes were scanned on
an Odyssey™ Infrared Imager at a resolution
of 169 µm.
Results
Reproducibility of the IR Detection
Method
To assess reproducibility of the IR detection
method, 40,000 cells from a breast cancer
patient tumor specimen were procured via
LCM, lysed and analyzed in triplicate for total
ERK levels using biotinylated rabbit anti-ERK
followed by detection with IRDye™ 800CW-
labeled goat anti-rabbit IgG (Fig. 2). ERK pro-
tein was detected over a broad dynamic linear
range in all triplicate runs. Error bars for the
standard deviations at each dilution are
shown, but were too small to be seen on this
scale. Coefficients of variance (CVs) for each
dilution were less than 7%, indicating that the
IR based method achieved very good repro-
ducibility across a broad linear detection range.
Because the absolute concentration of the
target proteins in the tumor samples is
unknown, we compared the sensitivity of the
IR detection method to the CSA method by
dilution analysis. On this basis, the sensitivity
of the IR detection was comparable or even
slightly better to than that achieved by colori-
metric based detection (Fig. 3). 
Multiplexing Signaling Endpoints 
From the Same Array
The ability to detect both the non-
phosphorylated and the phosphorylated forms
of the same protein using the same array was
determined using a lysate study set prepared
from human breast cancer epithelium obtained
from three different subjects and a control cell
line lysate (Jurkat T cells). One of the patients
was previously known to have low levels of
phosphorylated ERK compared to the other
two cases within this study set. The samples
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Fig. 2. Reproducibility of ERK kinase protein detection using infrared dye detection. A lysate, prepared from cells
obtained from a single human breast cancer specimen (BR36015), was arrayed in triplicate in a stepwise series
of twofold dilutions and stained with rabbit anti-ERK followed by detection with IRDye800CW-labeled goat anti-
rabbit.Assessment of linearity and reproducibility of the average of the three rows is shown on the right.
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were blinded prior to analysis. Each lysate
was arrayed in triplicate (Fig. 4) and the ana-
lytes were detected using anti-phospho ERK
IgG (mouse) and anti-total ERK IgG (rabbit)
followed by Alexa Fluor 680 goat anti-mouse
IgG and IRDye800CW goat anti-rabbit IgG on
the same array. The overlaid images showing
both the phospho and total levels of ERK are
shown on the left with the individual readouts
from each separate channel shown on the
right. As expected, cases 1 and 2 revealed
much higher levels of phosphorylated ERK
compared to case 3. Total ERK levels con-
tained in each of the three cases were found to
be nearly equivalent and reflected the equiva-
lent total protein levels in each lysate. This
result indicates the feasibility of assessing both
phospho and total protein levels of important
signal pathway mediators such as ERK kinase
from clinical material on a single array and
within the same spot. Interference experiments
performed by Western blotting of lysates and
comparison of signal outcomes where either
both total and phospho were measured
together, or individually, indicated that neither
primary was interfering with the ability of the
other to recognize the denatured epitope on
the membrane (data not shown).
Discussion
As the drug discovery field focuses on the
development of molecular-targeted therapeu-
tics, the activity status of pathways and phos-
phorylated levels of kinases and kinase
substrate targets of interest in individual
tumors will become a major focal point of
analysis. Gene microarray transcription profil-
ing alone cannot accurately recapitulate the
states of these pathways and posttranslational
modification events, and will be greatly com-
plemented by proteomic analysis of the phos-
phorylation states of cellular circuitry. The
detection of subtle changes in the activity of
various signaling pathways in normal and
tumor tissue in a patient is not only valuable
scientifically for the study of disease progres-
sion, but will be essential for appropriate treat-
ment selection and monitoring treatment
efficacy in the future. This is especially so now,
more than ever, because the drug develop-
ment pipeline is heavily skewed towards
signal pathway modulators and kinase
inhibitors (24–31).
Reverse-phase protein microarray technology
provides a means to detect, in a highly multi-
plexed way, the phosphorylation-mediated
changes that are the direct targets for therapy.
The reverse-phase protein array has shown
the unique ability to analyze signaling path-
ways using small numbers of human tissue
cells microdissected from biopsy specimens
(17–23). A comparison of this method with
tissue arrays (32) or antibody arrays (33–36)
reveals several unique advantages: (1) the
reverse-phase array employs denatured
lysates so that the antigen retrieval issues, cur-
rently a large limitation for tissue arrays, are
significantly reduced; (2) because each lysate
sample is arrayed in a miniature dilution
curve, a means of providing an internal stan-
dard curve to assess linear dynamic range is
directly ascertained, thus generating direct
quantitative measurements; and (3) the arrays
do not require direct tagging of the protein for
detection, as would be required for antibody
or forward phase (23) arrays, yielding a dra-
matic improvement in reproducibility, sensi-
tivity and robustness of the assay over other
techniques. An additional new benefit now
highlighted in this study is that with a two-
channel near IR-based system, we have the
ability to effectively double the number of
endpoints one could analyze with a fixed
number of arrays. Because clinical material is
always limiting and the number of signaling
endpoints quite large, any inability to multi-
plex the process can have substantial practical
impact.
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Fig. 3. Sensitivity of infrared detection on reverse phase arrays. (A) Multiple breast tumor samples were spot-
ted onto nitrocellulose-coated slides along with 1:3 and 1:9 serial dilutions of each sample and subjected to
detection of PKC-α using the CSA technique. Samples 1, 2, and 3 are noted. (B) In parallel, serial twofold dilu-
tions of three of the breast tumor samples, labeled samples 1, 2, and 3, were subjected to analysis of PKC-α
using infrared detection. (C) Tabulation of the detection endpoints of each technique for samples 1, 2, and 3.
Fig. 4. Multiplexed detection of phosphorylated and total ERK protein levels in breast cancer tissue cells.
Tissue cells from three cases of human breast cancer were obtained and lysates prepared from these and from
a cell line control prepared from Jurkat T cells. The array was probed simultaneously for phospho and total
ERK levels using phospho-ERK (mouse) and total ERK (rabbit) antibodies and then Alexa Fluor680 goat anti-
mouse and IIRDye800CW goat anti-rabbit antibodies on the same array. The overlaid images of both the
phospho and total levels of ERK are shown on the left, with the individual readouts from each channel shown
on the right (phospho-ERK: top right; total ERK: bottom right).
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The current liability with a colorimetric
detection system is that only one analyte per
slide can be evaluated. The dual IR dye
method appears reproducible, is relatively
simple, and can be performed with commer-
cially available reagents. A limitation, how-
ever, to the IR dye-labeled secondary antibody
approach is that a dual-endpoint analysis with
anti-pan and anti-phospho protein antibodies
is only currently achievable when sets of anti-
bodies derived from two different species are
available for a given analyte. Alternatively, if a
matching pan-antibody is not available, the
samples can be normalized against a house-
keeping protein. Further assessments to deter-
mine any sensitivity limitations of IR-based
detection need to be performed on larger
study sets to evaluate the potential for opti-
mization for this type of detection method.
Today, micro, and even nano-proteomic
technologies are being developed such that the
field of clinical proteomics will have direct
bedside impact. It is possible that the physi-
cian will soon use these different proteomic
tools at multiple steps within disease manage-
ment and therapeutic intervention. In the
future, a clinician may routinely employ tech-
nologies to map the state of molecular net-
works within biopsy samples. Functional
maps of the state of key pathways within a
patient’s tumor cells will become the starting
point for personalized therapy. Under this sce-
nario, therapy can be tailored to the individ-
ual tumor’s molecular defect. Moreover, it
should be feasible to administer combination
therapy targeting multiple interdependent
points along a pathogenic pathway, or target-
ing separate pathways (37–38).
On-going clinical trials at the National
Cancer Institute have currently incorporated
reverse phase microarray technology for
evaluation of the sample procurement and
processing technologies, and to elucidate
hypotheses concerning treatment effects on
cell signaling networks. As more cell signaling
information is gleaned from protein microar-
rays, we envision an enhanced ability to
develop/identify new combinatorial therapies
or targeted therapies. The ability to determine
and understand treatment effectiveness, via
protein microarrays, which can analyze both
the drug target and the entire pathway net-
work, may lead to better patient management
and better clinical outcomes.
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